ClinicalTrials.gg
Not yet recruitingNCT03606538Updated Oct 30, 2024

MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

A Phase 1 interventional study of Midomafetamine HCl in Pharmacokinetics and Hepatic Impairment, sponsored by Lykos Therapeutics. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial to learn how MDMA is processed in people with abnormal liver function.

The main questions it aims to answer are:

Do people with abnormal liver function experience greater absorption of MDMA? Does the dose of MDMA need to be adjusted in people with abnormal liver function?

Researchers will compare people with abnormal liver function to people with normal liver function.

Participants will receive a single dose of MDMA then undergo periodic vitals measurements. They will remain at the study site for two more days undergoing more vitals measurements and having subjective effects and adverse events measured.

Read the detailed description

This protocol is for a Phase 1, open-label study with a primary purpose of evaluating the effect of moderate hepatic impairment in the pharmacokinetics of MDMA and its active metabolite, 3,4-methylene-dioxyamphetamine (MDA), and determining whether an adjustment to the dosage would be indicated in this group of patients in comparison to patients with normal liver function. Because people with moderate hepatic impairment may experience greater exposure to drug than people without it, the secondary purpose of this study is to evaluate the effect of moderate hepatic impairment on the safety and tolerability of oral MDMA, with special attention to ECG data. The study will enroll eight participants, ages 18 to 65 years old, with moderate hepatic impairment, and eight healthy controls with normal hepatic function who are matched with participants with moderate impaired hepatic function on the basis of age, weight and gender.

Participants who give their written informed consent will be screened for study participation that will include a physical examination, assessing current and prior medical and physical health, and a baseline electrocardiogram (ECG) reading. If applicable, they may begin tapering off any contraindicated psychiatric medication. Participants who meet study criteria will receive a single dose of 80 mg midomafetamine HCl on the first day of a three-day stay at the study site.

Blood will be collected periodically in order to calculate pharmacokinetics of MDMA and its active metabolite methylenedioxyamphetamine (MDA). Blood will be collected ten times on Day 1 (-5 min, 0 hours (drug administration), 0.5 h, 1, 2, 4, 6, 7, 10 and 12 hours), starting five minutes before drug administration. Subjective effects of MDMA will be assessed through 15 visual analog scales at similar time points to blood collection, at 0.5, 1, 2, 4, 6 and 7 hours post-drug. There will be six 12-lead ECG measurements on Day 1.

Participants will remain at the study site for two more days. Drug safety will be assessed by measuring blood pressure, heart rate and body temperature after MDMA administrations, collecting adverse events throughout the study and measuring suicidal thoughts or behaviors with the Columbia Suicide Severity Rating Scale (C-SSRS). Blood will be collected 24 and 36 hours after drug administration, and ECG will be performed on Day 2, and a single ECG and blood draw will occur on Day 3, 4 and 5. Participants will return for eight and 15 days after drug administration. They will have a single blood draw on each day. The study ends 15 days after drug administration, approximately one month after screening.

The primary outcome measure will be area under the curve from dosing to last dose (AUC) of MDMA and MDA. AUC will be computed from plasma collected multiple times after a single dose of MDMA, twice on the day following the day of drug administration, and once daily for three more days. Other pharmacokinetic measures will be maximal values of MDMA and MDA (Cmax), and time to reach maximum MDMA and MDA levels (Tmax). Safety measures will also include a comparison of subjective effects across groups, ECG readings, number of adverse events, and suicidal ideation or behavior as measured via C-SSRS during the study.

02

Conditions studied

  • Pharmacokinetics
  • Hepatic Impairment

Keywords

  • MDMA
  • metabolism
  • methylenedioxymethamphetamine
  • midomafetamine
03

In context

Lead sponsor

Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with moderate hepatic impairment (class B according to Child- Pugh's criteria).
  • Participants with normal hepatic function: no findings from medical history, physical examination, laboratory values within protocol defined parameters.
  • Age 18 to 65 years.
  • Weight > 45 kg
  • Negative Carbohydrate Deficient Transferrin blood test at Screening and negative breathalyzer alcohol test prior to trial drug administration.
  • Negative urine test for drugs of abuse at Screening and prior to trial drug administration.
  • Able to comprehend and willing to sign an form.

Exclusion criteria

Exclusion Criteria:

  • Have a current psychiatric diagnosis.
  • Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of .
  • Have acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function as indicated by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment within 2 weeks.
  • Have liver disease; esophageal variceal bleeding within 6 months prior to screening, unless successfully treated with banding, or gastric varices.
  • Have spontaneous bacterial peritonitis within 3 months prior to screening.
  • Have a portosystemic shunt, organ transplant, Wilson's disease, cholestatic liver disease (e g, primary biliary cirrhosis or primary sclerosing cholangitis)
  • Evidence or history of significant hematological, endocrine, cerebrovascular, cardiovascular (including controlled hyper-tension), coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of MDMA administration.
  • For moderate hepatic impairment participants: have laboratory findings except as related to hepatic impairment.
  • For control participants only: have clinically significant laboratory results outside the normal limits, including >48 U/L, ALT > 55 U/L, GGT > 48 U/L, > 1.2 mg/dL or \< 12 g/dL.
  • Have a history of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject.
  • Have any positive test for drugs of abuse and /or alcohol at screening.
  • Have a history or presence of clinically significant abnormal 12-lead or an ECG with by Bazett's correction of > 450 ms in men, > 470 ms in women on the screening ECG.
  • Have a PR interval > 240 ms, QRS > 110 ms or a history of prolongation of QT interval.
  • Have mental incapacity, unwillingness or language barriers precluding adequate understanding or subject co-operation.
  • Are unwilling to stay in the clinical unit for the required duration as per the protocol.
  • Have a known or suspected allergy to trial product or related products.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Moderate hepatic impairment

    Eight participants with moderate hepatic impairment receive a single dose of 80 mg midomafetamine HCl.

    Drug: Midomafetamine HCl

  • Experimental
    Normal hepatic function

    Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg midomafetamine HCl.

    Drug: Midomafetamine HCl

Interventions

  • 80 mg midomafetamine HCl

    Also known as: MDMA, 3,4-methylenedioxymethamphetamine, midomafetamine, MDMA HCl

06

What researchers measure

Primary outcomes

  1. Area under curve from dosing time to last measurement (AUC(0-t)) - MDMA

    Computed exposure to MDMA using blood collected periodically at 1, 2, 4, 6, 7, 10, 12, 24, 36, 48, 72 and 96 h post drug

    Time frame: 0 to 5 days after drug administration

  2. Area under curve from dosing time to last measurement (AUC(0-t) MDA

    Computed exposure to MDA using blood collected periodically at 1, 2, 4, 6, 7, 10, 12, 24, 36, 48, 72 and 96 h post-MDMA administration

    Time frame: 0 to 5 days after drug administration

Secondary outcomes

  1. Peak MDMA (Cmax)

    Maximum value of plasma MDMA in nglml

    Time frame: 0 to 5 days after drug administration

  2. Peak MDA (Cmax)

    Maximum value of plasma MDA in ng/lml

    Time frame: 0 to 5 days after drug administration

  3. Time to maximum (Tmax) MDMA

    Time to reach maximum plasma values of MDMA

    Time frame: 0 to 5 days after drug administration

  4. Time to maximum (Tmax) MDA

    Time to reach maximum plasma values of MDA

    Time frame: 0 to 5 days after drug administration

  5. Area under curve from dosing time to infinity (AUC(0-infinity)) - MDMA

    Computed exposure to MDMA using blood collected periodically at 1, 2, 4, 6, 7, 10, 12, 24, 36, 48, 72 and 96 h post drug

    Time frame: 0 to 5 days after drug administration

  6. Area under curve from dosing time to infinity (AUC(0-infinity)) - MDA

    Computed exposure to MDA using blood collected periodically at 1, 2, 4, 6, 7, 10, 12, 24, 36, 48, 72 and 96 h post drug

    Time frame: 0 to 5 days after drug administration

  7. 90% CL between hepatic impaired and no hepatic impairment groups for AUC (0-t)

    90% confidence interval (CI) for the ratio of population geometric means between moderate hepatic impairment and normal hepatic function for AUC (0-t)

    Time frame: 0 to 5 days after drug administration

  8. 90% CL between hepatic impaired and no hepatic impairment groups for AUC (0-infinity)

    90% confidence interval (CI) for the ratio of population geometric means between moderate hepatic impairment and normal hepatic function for AUC(0-infinity)

    Time frame: 0 to 5 days after drug administration

  9. 90% CL between hepatic impaired and no hepatic impairment groups for Cmax

    90% confidence interval (CI) for the ratio of population geometric means between moderate hepatic impairment and normal hepatic function for Cmax

    Time frame: 0 to 5 days after drug administration

  10. Change in QTcI - Baseline to 0.5 h post drug

    Change in ECG QTcl from Baseline compared to 0.5 h post MDMA

    Time frame: 0 days after drug administration

  11. Change in QTcI - Baseline to 2 h post-drug

    Change in ECG QTcl from Baseline compared to 2 h post MDMA

    Time frame: 0 days after drug administration

  12. Change in QTcI Baseline to 4 h post-drug

    Change in ECG QTcl from Baseline compared to 4 h post MDMA

    Time frame: 0 days after drug administration

  13. Change in QTcI Baseline to 6 h post-drug

    Change in ECG QTcl from Baseline compared to 6 h post MDMA

    Time frame: 0 days after drug administration

  14. Change in QTcI Baseline to 7 h post-drug

    Change in ECG QTcl from Baseline compared to 7 h post MDMA

    Time frame: 0 days after drug administration

  15. Change in QTcI Baseline to 1 d post-drug

    Change in ECG QTcl from Baseline compared to 1 d post MDMA

    Time frame: 1 day after drug administration

  16. Change in QTcI Baseline to 2 d post-drug

    Change in ECG QTcl from Baseline compared to 2 d post MDMA

    Time frame: 2 days after drug administration

  17. Change in QTcI Baseline to 3 d post-drug

    Change in ECG QTcl from Baseline compared to 3 d post MDMA

    Time frame: 3 days after drug administration

  18. Change in QTcI Baseline to 4 d post-drug

    Change in ECG QTcl from Baseline compared to 4 d post MDMA

    Time frame: 4 days after drug administration

  19. Pre-drug Systolic blood pressure (SBP)

    First SBP measurement, prior to drug administration, on day of drug administration

    Time frame: 0 days after drug administration

  20. Peak Systolic blood pressure (SBP)

    Maximum value of SBP measured during day of drug administration

    Time frame: 0 days after drug administration

  21. Final systolic blood pressure (SBP)

    Last SBP measurement taken on day of drug administration

    Time frame: 0 days after drug administration

  22. Pre-drug Diastolic blood pressure (DBP)

    First DBP measurement, prior to drug administration, on day of drug administration

    Time frame: 0 days after drug administration

  23. Peak Diastolic blood pressure (DBP)

    Maximum value of DBP measured during day of drug administration

    Time frame: 0 days after drug administration

  24. Final Diastolic blood pressure (DBP)

    Last DBP measurement taken on day of drug administration

    Time frame: 0 days after drug administration

  25. Pre-drug heart rate (HR)

    First HR measurement, prior to drug administration, on day of drug administration

    Time frame: 0 days after drug administration

  26. Peak heart rate (HR)

    Maximum value of HR measured during day of drug administration

    Time frame: 0 days after drug administration

  27. Final heart rate (HR)

    Last HR measurement taken on day of drug administration

    Time frame: 0 days after drug administration

  28. Pre-drug body temperature (BT)

    First body temperature measurement, prior to drug administration, on day of drug administration

    Time frame: 0 days after drug administration

  29. Peak body temperature (BT)

    Maximum BT value measured during day of drug administration

    Time frame: 0 days after drug administration

  30. Final body temperature (BT)

    Last BT measurement taken on day of drug administration

    Time frame: 0 days after drug administration

  31. Number of AEs reported

    Number of AEs reported in each group from enrollment to study end

    Time frame: -4 days to 15 days post drug administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — We will share outcome data appearing in any published reports upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data and study-related documents will be available when all participants have completed the study

Access criteria: Interested persons should correspond with the central contact for the multisite study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Dec 2028, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2018
First posted
Jul 31, 2018
StartEst.
Mar 29, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03606538
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Jul 31, 2018
Start date
Mar 29, 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 30, 2024

Study contacts

Recruitment Officer
Contact
recruitment@lykospbc.com
Janel Long-Boyle, PharmD, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion